Examl 1:l NU641/l NUl 641l (Latestl 2025/l
2026l Update)l Advancedl Clinicall Pharmacologyl Guide|l Questionsl &l Answers|l Gradel A|l 100%l Correctl (Verifiedl Solutions)-l Regis
Q:l DEAl number
Answer:
Drugl Enforcementl Agencyl Numberl -l numberl providedl tol HCP,l manufacturers,l distrubtes,l allowingl theml tol writel prescriptionsl forl controlledl substances everyl 2l years notl insurancel billingl number
Q:l Controlledl substancel classification
Answer:
1:l nol acceptedl medicall use,l nol legall use,l researchl onlyl (heroin,l LSD)
2:l nol refills,l mustl bel writtenl order,l validl forl 30l days,l typicallyl onlyl 30l dayl supplyl (narcotics,l stimulants,l depressants)l 3:l telehphonel sciptl okay,l paperl versionl tol pharml withinl al week,l 6l monthl script,l 30l dayl supplyl (codinel inl combination,l steroids,l depressants,l lessl intensel steroids)
4:l samel asl one,l justl illegall positionl rulesl arel differnt
5:l samel asl 3l (lomitl,l pregab)
6:l massl thing,l everythingl else
Q:l Thel patientl wasl givenl al prescriptionl forl al brand-namel diabeticl medication.l Shel wasl veryl surprisedl tol seel al differentl namel forl thel medicationl onl herl bottle,l butl alsol veryl pleasedl thatl thel medicationl camel atl nol cost.l Becausel shel wantedl tol bel carefull andl knowl thatl shel wasl takingl thel correctl medication,l thel patientl calledl thel APN.l Whichl responsel byl thel APNl isl mostl appropriate? 1 / 4
A.l Thel APNl shouldl telll thel patientl thatl becausel thel namel isl notl whatl wasl prescribed,l thel patientl shouldl takel thel medicationl backl tol thel pharmacyl becausel itl isl mostl likelyl al mistakel onl thel partl ofl thel pharmacy B.l Thel APNl shouldl informl thel patientl thatl pharmacistsl mayl substitutel al genericl equivalentl forl al brand-namel drugl unlessl thel prescriberl specifiesl "Dispensel asl Written"l onl thel prescription C.l Thel APNl shouldl makel surel thatl thel patientl isl notl confusedl aboutl whichl prescriptionl shel tookl tol thel pharmacy,l becausel thisl couldl bel thel reasonl thel bottlel ha
Answer:
b
Q:l Al patientl tellsl thel APNl thatl hel hasl severel rightl shoulderl painl thatl isl constantl andl sharp.l Hel looksl anxiousl andl appearsl tol bel inl pain.l Uponl examination,l hel criesl outl whenl thel APNl rotatesl hisl shoulder.l Thel APNl wantsl tol sendl himl forl anl x-ray,l butl hel statesl hel cannotl standl thel painl anotherl moment.l Thel APNl prescribesl al controlledl substancel painl relieverl forl thel patient,l butl thel APNl isl concernedl thatl thel patientl mayl havel receivedl painl medicationl froml otherl providers.l Howl canl thel APNl determinel whetherl thisl isl thel case?A.l Thel APNl mustl relyl onl thel patientl tol bel honestl aboutl whetherl orl notl hel hasl receivedl otherl prescriptionsl forl painl medications B.l Thel APNl canl calll thel U.l S.l Drugl Enforcementl Administrationl (DEA)l hotlinel andl askl aboutl thel patient'sl historyl ofl controlledl substancel drugl use C.l Throughl thel usel ofl technology,l thel APNl canl accessl thel state'sl controlledl substancel databasel tol findl outl ifl otherl prescriptionsl forl pain
Answer:
c
Q:l primaryl vsl secondaryl HTN
Answer:
*Primaryl HTN -unknownl etiology -95%l ofl cases *Secondaryl HTN -duel tol identifiablel causel =l 5%l ofl cases -renall issues,l endocrine,l sleepl apnea,l coaractionl ofl thel aorta
- / 4
Q:l BP
Answer:
=l COl (strokel volumel xl HR)l Xl PVRl (alsol knownl asl systemicl vascularl resistancel impactedl by -baroreceptors=l aortic,l andl carotid -endotheliall factors=l HTNl stimulatesl smoothl musclel growthl andl atherosclerosisl -kidneysl involvedl withl RASSl systeml (Angiotensinl IIl increasesl PVR,l stimulatesl smoothl musclel growthl andl mayl contributel tol atheroscelerosis
Q:l Pharmacodynamicsl ofl diuretics
Answer:
-reducel ECF,l mainlyl impactsl strokel volumel thiazide:l typicallyl firstl line,l inhibitl sodiuml resorptionl inl thel distall renall tubulel (hydrochlorothiazide,l metolazonel *strongestl ofl thel group) loopl diretics:l inhibitl sodiuml reabsorptionl inl thel ascendingl loopl ofl Henlel (morel potent)l (furosimidel andl torsemide) potassiuml sparingl :l inhibitl excretionl ofl potassiuml distallyl (amloridel andl triamterene) aldosteronel antagonist:l potassiuml sparing,l inihibtisl effectl ofl aldosteronel onl distall renall tubulesl (spironolactone)
Q:l Pharmcokineticsl ofl diuretics
Answer:
-loopl diureticsl havel shortl plasmal halfl lifel (prescribedl atl shorterl interval),l thiazidel andl potassiuml sparingl diureticsl havel longerl plasmal halfl lifes -excretedl mostlyl unchangedl inl thel urine
Q:l ARDsl andl precautionsl ofl diuretics
Answer:
precations:l goutl orl kidneyl stones,l olderl adults
Pregl classl cl andl B
ADRs:l 3 / 4
thiazide,l loop:l hypokalemia,l hyponatremia,l hypomagnesemia,l HYPERCALCEMIA
potassiuml sparing:l hyperkalemial
hypotension,l glucosel intolerance,l +l uricl acid
spironalactone:l gynecomastia,l importancel (lacksl aldosterone)
thiazide:l photosensitivity,l hyperlipidemia
Q:l drugl interactionsl andl monitoringl withl diueretics,l use
Answer:
interactions:l lithiuml (inihibitl excretionl withl thiazidel andl loop)
use:l hypertension,l edema,l HF
monitoring:l HR,l BP,l edema,l weightl gain,l urinel output,l BMPl
takel beforel 4pm*
Q:l Antiotensin-l convertingl enzymel inhibitorsl (ACEI)l pharmacodynamics
Answer:
-prilsl (catoprill notl usedl often,l firstl inl classl shortl halfl life) -lowersl SVRl andl decrceasesl strokel volumel (froml waterl retention),l samel asl ARBS blocksl thel conversionl ofl angiotensionl Il tol angiotensinl II -increasesl reninl activityl andl decresesl vasopressinl (ADH)l secrtion -reducedl aldosteronel secretion,l akal decreasesl bloodl volume -secondaryl action:l inhibitsl brakdownl ofl bradykinase->l increasesl vasodilation
Q:l ACEl pharmcokinetics,l contraindications,l interactions
Answer:
pharmockinetics:l 1-2l hourl onsetl andl durationl ofl actionl 24l hrs
contraindications:l angioedema,l PREGNANCY
interactions:l nsaidsl (renall tox),l lithium,l sacrubtrill (samel pathways),l azathiloprinel ADRS:l hyperkalemia,l *dryl cough,l bloodl dyscrasias,l acutel renall failurel (startl atl lowl dose)l andl jaundice
Q:l ACEIl usesl andl monitoringl parameters
- / 4